Neurotoxicity

CD19-Targeting Therapies Show Remarkable Growth, Revolutionizing Cancer Treatment with High Response Rates - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Antibody, Tisagenlecleucel, IND, Acute leukemia, Fast Track, CD19, B-cell lymphoma, Hematological Cancer Research Investment and Education Act, Research, Neurotoxicity, Quality of life, Novartis, Indication, Immune system, Cytokine release syndrome, USD, NHL, CRS, Lymphoid leukemia, Therapy, Patient, Non-Hodgkin lymphoma, ALL, Monoclonal antibody, Vaccine, Pharmaceutical industry, Amgen

Market Opportunity: The global CD19 antibody market is projected to exceed USD 10 billion by 2028, showcasing its remarkable growth potential.

Key Points: 
  • Market Opportunity: The global CD19 antibody market is projected to exceed USD 10 billion by 2028, showcasing its remarkable growth potential.
  • Commercially Approved CD19 Antibodies: Currently, there are 10 approved CD19 antibodies available in the market, indicating a diverse range of treatment options for patients.
  • These therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell (CAR-T) therapies, have made a significant impact on cancer treatment.
  • To date, nine CD19-targeting therapies have received approval from regulatory bodies, including bispecific antibodies, monoclonal antibodies, antibody-drug conjugates, and CAR-T therapies.

Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program

Retrieved on: 
Wednesday, November 8, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, SLE, Lupus nephritis, IND, CD16, CD20, Northwest Biotherapeutics, GVHD, Neurotoxicity, ADCC, NK, Cancer, Cytokine release syndrome, Rituximab, Immunotherapy, Autoimmune disease, Safety, Hospital, Patient, Lupus, Vaccine

This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.

Key Points: 
  • This year’s program attracted more than 1,500 nominations from over 12 different countries throughout the world.
  • Seminal clinical data with autologous CAR-T cells suggests that deep B cell depletion can induce complete and long-lasting responses in patients with lupus nephritis.
  • “The use of autologous CAR-T cells requires apheresis, likely hospitalization, and the potential for serious side effects.
  • “We’re pleased to recognize Artiva with ‘Immunology Innovation of the Year’ for their pipeline of off-the-shelf, allogeneic NK cell therapies that have the potential to be safe and immediately accessible to patients in need,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards.

Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Retrieved on: 
Monday, November 6, 2023
Multiple myeloma, MD, Society, ASH, Neurotoxicity, Hospital, LOS, Exposition, Patient, Toxic epidermal necrolysis, Nursing

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “75% of patients on multiple myeloma CAR-T waiting lists at U.S. hospitals do not receive the CAR-T therapy.
  • As CAR-Ts are expected to be approved for earlier lines of treatment, we believe demand is likely to increase,” said Ilya Rachman, MD PhD, Executive Chairman of Nexcella.
  • “We are working tirelessly to make NXC-201 an option for these patients waiting for multiple myeloma CAR-Ts.”
    “Today, only 5% of U.S. hospitals offer multiple myeloma CAR-Ts due to toxicities,” said Gabriel Morris, President of Nexcella.
  • “Our N-GENIUS technology platform, which we believe overcomes neurotoxicity, aims to allow the remaining 95% of U.S. hospitals, including community hospitals, to offer our CAR-T NXC-201.”
    65th ASH Annual Meeting and Exposition, San Diego, CA

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Retrieved on: 
Monday, November 6, 2023
Multiple myeloma, MD, Society, ASH, Neurotoxicity, Hospital, LOS, Exposition, Patient, Financial toxicity, Nursing

LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

Key Points: 
  • “75% of patients on multiple myeloma CAR-T waiting lists at U.S. hospitals do not receive the CAR-T therapy.
  • As CAR-Ts are expected to be approved for earlier lines of treatment, we believe demand is likely to increase,” said Ilya Rachman, MD PhD, Chief Executive Officer of Immix Biopharma.
  • “We are working tirelessly to make NXC-201 an option for these patients waiting for multiple myeloma CAR-Ts.”
    “Today, only 5% of U.S. hospitals offer multiple myeloma CAR-Ts due to toxicities,” said Gabriel Morris, Chief Financial Officer of Immix Biopharma.
  • “Our N-GENIUS technology platform, which we believe overcomes neurotoxicity, aims to allow the remaining 95% of U.S. hospitals, including community hospitals, to offer our CAR-T NXC-201.”
    65th ASH Annual Meeting and Exposition, San Diego, CA

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Neoplasm, Nivolumab, MSI, Cell, Testicular cancer, Memorial Sloan Kettering Cancer Center, Neurotoxicity, SITC, Immunotherapy, Cytokine release syndrome, Mink, Annual general meeting, Lung cancer, Society, Cancer, Therapy, Patient, HLA, Failure, Phosphorus, Vaccine, Pharmaceutical industry, Medical imaging

AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.

Key Points: 
  • AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.
  • AgenT-797 was detected in the periphery for up to 6 months and persistence was independent of HLA matching.
  • An increased level of immune cell tumor infiltration and neoantigen driven expansion of anti-tumor cytotoxic T cells was observed following administration.
  • Expansion of clinical programs are underway in additional solid tumor settings, including relapsed/refractory gastric cancer.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Patient, Cyclophosphamide, Infrared spectroscopy correlation table, Graft-versus-host disease, CD19, CD22, CDMO, Society, Neurotoxicity, ASH, Alemtuzumab, Hematology, Euronext Growth, San Diego Convention Center, Clinical trial, Cytokine release syndrome, Relapse, DLT, Allotransplantation, B-ALL, NHL, CRS, FCA, Investigational New Drug, Pharmaceutical industry, Medical device, Cosmetics, Vaccine

Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.

Key Points: 
  • Cytokine release syndrome (CRS) Grade 1 or 2 occurred in all patients, and all CRS resolved with treatment.
  • No immune effector cell associated neurotoxicity (ICANS) or graft versus host disease (GvHD) was observed.
  • There were no UCART20x22 dose limiting toxicities (DLTs), and there was 1 DLT in connection with CLLS52 (alemtuzumab).
  • The study continues to enroll patients at dose level 2i (2.5 million cells/kg) with UCART22 P2.

ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neur

Retrieved on: 
Wednesday, November 1, 2023
Intellectual disability, Inflammasome, EAE, ASC, Mouse, NLRP3, Microglia, Neuroprotection, Phenotype, Inflammation, Research, Brain, Neurotoxicity, Neuroinflammation, Immunomodulation, M1, Molecular neuroscience, Multiple sclerosis, Spinal cord, Astrocyte, Disability, Therapy, Neuroscience, Super Meat Boy, MS, Central nervous system, Pharmaceutical industry

ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • Key findings showed that NLRP3 inflammasome inhibition:
    Ameliorated pathological changes in the spinal cord and neuron damage in the brain of MS mice.
  • “It is encouraging that the research published in Molecular Neurobiology substantiates our published MS data with Inflammasome ASC Inhibitor IC 100, providing support for its use as a potential therapeutic option.
  • By inhibiting ASC, IC 100 blocks formation of NLRP3 and other types of inflammasomes to block initiation of the inflammatory cascade.

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

Retrieved on: 
Tuesday, October 31, 2023
Survival, CAR, IRB, ESMO, DCR, Diarrhea, Neurotoxicity, Congress, SD, Cytokine release syndrome, Oncology, ORR, RECIST, European Society for Medical Oncology, CRS, ICT, Patient, OS, Pharmaceutical industry

ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.

Key Points: 
  • ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.
  • Presentation details were as follows:
    This presentation highlights updated survival data from the 21 subjects who were enrolled in two dose escalation groups in IRB-approved studies in China.
  • The median OS is approximately 24 months in dose level 2 with 4 of the 8 patients still alive.
  • The Company’s Phase 1 study of GCC19CART is enrolling patients with R/R mCRC at multiple sites in the U.S.

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
Tuesday, October 31, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Amyloid, Czech Institute For International Meetings, AD, Ageing, Plaque, Organic chemistry, CSF, APOE4, MD, Symposium, Genotype, Doctor of Philosophy, Lotte New York Palace Hotel, Cerebrospinal fluid, Truist, Early, Risk, NDA, Safety, Patient, Neurotoxicity, Pharmaceutical industry, Alzheon

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, CD3, Antigen, Northwest Biotherapeutics, Neurotoxicity, SITC, Immunotherapy, Neoplasm, Risk, Annual general meeting, Safety, Monoclonal antibody, Pharmaceutical industry, Vaccine

EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, California, from November 3-5.

Key Points: 
  • EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting to be held in San Diego, California, from November 3-5.
  • This poster presentation will feature initial safety, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) data from the Phase I dose escalation study in relapsed or refractory multiple myeloma (NCT04735575; CTR20212633).
  • The presentation details are as follows:
    “We are very pleased to share the EMB-06 data as a late-breaker at the SITC Annual Meeting.
  • “With multiple T cell engagers in our clinical and pre-clinical pipeline, EpimAb is looking forward to realizing the promising potential of this modality and to creating novel therapies for diseases with significant unmet need.”